Uğur Şahin
Co-Founder & CEO
mRNA technologycancer immunologytranslational medicine
Details
- ●Modalities: mRNA vaccines, mRNA immunotherapies, antibody-drug conjugates, CAR-T cell therapy, bispecific antibodies
- ●Therapeutic areas: oncology, infectious diseases, autoimmune
- ●Key targets: Claudin-6, Claudin-18.2, GPC3, HER2, patient-specific neoantigens
- ●Indications: COVID-19, melanoma (individualized neoantigen vaccine), pancreatic cancer, non-small cell lung cancer
- ●Funding: N/A (public since 2019, €18.7B COVID vaccine revenue 2021-2022)
Partners & investors
- Public (NASDAQ: BNTX)· Investor
Key considerations
- ●AI tools in use: InstaDeep AI subsidiary (acquired 2023), Proprietary mRNA sequence optimization, DeepChain protein design (via InstaDeep)
- ●Acquired InstaDeep for ~$680M to integrate AI across R&D
- ●InstaDeep's DeepChain for protein engineering and mRNA optimization
- ●AI-driven individualized neoantigen prediction for cancer vaccines
Pipeline
- Phase 22
- Phase 31
- Approved1
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Özlem Türeci
Co-Founder & Chief Medical Officer
oncologyimmunotherapyclinical development